You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.
WUSTL spinout PercayAI will provide augmented intelligence technology to Canopy Biosciences' RNA-seq and NanoString tests to inform drug discovery.
The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.
The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells.
The firms will collaborate to develop Synlogics pipeline of synthetic medicines using Ginkgo's microbial programming and optimization platform.
Revolution Medicines had been looking to sell Warp Drive's genomic drug discovery platform and microbial genome database since acquiring them in 2018.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.